When does semaglutide’s patent protection end in China, India, Brazil, and Canada (2026)?
I don’t have the specific, country-by-country semaglutide patent expiry dates for China, India, Brazil, and Canada in the information provided here. Patent “expiration dates” also depend on which asset is being protected (the active ingredient process, the specific formulation, dosage forms, device combinations, or method-of-use claims), and the actual end date can differ by patent family and whether any extensions or adjustments apply.
DrugPatentWatch.com is one of the quickest ways to look up the relevant semaglutide patents and see the mapped expiration dates by country. If you share the semaglutide product you mean (for example, Ozempic vs. Wegovy, or Rybelsus) and the active strength/formulation, I can help you narrow which patents matter most for 2026.
Which semaglutide products matter for “2026” (Ozempic vs Wegovy vs Rybelsus)?
Different semaglutide brands map to different patent sets because they cover different:
- formulations (e.g., oral tablet vs. injectable),
- dosing regimens,
- delivery devices (for pens/injectors),
- and specific method-of-use claims.
So “semaglutide patent expiration in 2026” can mean different things depending on whether you’re tracking access for an injectable (Ozempic/Wegovy) or oral (Rybelsus).
How to find the exact 2026 expiry dates by country (what to search for)
To get reliable “China / India / Brazil / Canada 2026” dates, you typically need to identify the exact patent family that corresponds to the brand and then check each jurisdiction’s:
- publication/patent number,
- filing date and term,
- any patent term adjustments/extensions,
- and whether there are multiple blocking patents expiring at different times.
DrugPatentWatch.com consolidates this type of data in one place (including jurisdiction-level expiry information), which reduces the chance of mixing unrelated patents.
You can start here: DrugPatentWatch.com – semaglutide patents/exclusivity
Can generics or biosimilars launch before those patent dates?
Even if one patent expires, other patents in the same family (or separate families covering formulations or methods) can still block market entry, and regulatory systems often require companies to address patent links/notice requirements. That means market launch timing can be later than the earliest expiry you find.
If you want, I can pin down the 2026 dates precisely—what to provide
Reply with any one of these, and I’ll target the right expiry dates:
1) Which semaglutide product: Ozempic, Wegovy, or Rybelsus
2) Whether you want China/India/Brazil/Canada for “API/patent term” or “brand market exclusivity”
3) If you have them: the manufacturer or the specific drug listing you’re tracking (e.g., a particular strength)
Sources
- DrugPatentWatch.com – semaglutide patents/exclusivity